Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice.

Minehiko InomataTakeshi TsudaTomomi IchikawaMasahiro MatsumotoIsami MizushimaKenji AzechiNaoki TakataNozomu MurayamaKana HayashiTakahiro HiraiZenta SetoKotaro TokuiYasuaki MasakiChihiro TakaSeisuke OkazawaKenta KambaraShingo ImanishiHirokazu TaniguchiToshiro MiwaRyuji HayashiShoko MatsuiKazuyuki Tobe

Published in: Thoracic cancer (2023)

The progression-free survival of patients who received systemic ICI therapy was 9.6 months, suggesting that ICI therapy might be effective in patients with pulmonary sarcomatoid carcinoma.

Keyphrases

free survival
pulmonary hypertension
clinical practice
stem cells
bone marrow